The pharmaceutical targeting of oncogenic kinase:pseudokinase units is challenging.4, 34, 46, 47, 48 One therapeutic target, which has been observed to be deregulated in a wide variety of human cancers, is the pseudokinase and human epidermal growth factor receptor 3 (HER3). The gene discussed is ERBB3; the disease is cancer.